Mark Youngblood
Has grant
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Evaluating STING as a Therapeutic Approach in Meningiomas
Open Date: 2024-07-01
Close Date: 2025-07-01
Grant: Close
Predicting Glioblastoma Response to Paclitaxel and Carboplatin After Opening the Blood-Brain Barrier
Open Date: 2024-04-15
Close Date: 2026-04-14
Grant: Close
Molecular Markers of Meningioma Growth Arrest After HDAC Inhibition
Open Date: 2022-07-01
Close Date: 2023-06-01
Grant: Close
Transcriptional Drivers of Aggressive Behavior in Meningiomas
Open Date: 2022-03-01
Close Date: 2023-03-01
Grant: Close
PBAF Signaling in Meningioma Tumorigenesis
Open Date: 2018-02-01
Close Date: 2019-05-31
Articles (21)
Meningiomas are common tumors of the central nervous system that are typically treated with surgery or radiation, but lack established systemic therapies. Activation of the stimulator of interferon genes pathway with an agonist such as 8803 can trigger anti-tumor immune responses. Using integrated molecular approaches, here we show that this pathway is targetable in both neoplastic and immune populations within the meningioma microenvironment. Meningioma tumor cells exhibit promoter hypomethylation and increased chromatin accessibility of the STING genomic locus, associated with robust expression of this gene. Treatment of diverse patient meningiomas ex vivo with 8803 induces direct tumor cytotoxicity through inflammatory cell death pathways, including induction of gasdermin D membrane pore formation. Release of necrotic tumor debris triggered by 8803 activates macrophages and upregulates matrix metalloproteinase production, facilitating degradation of extra-cellular collagen. Injection of preclinical meningiomas with 8803 induces survival benefits, including in an immunocompetent orthotopic setting, through remodeling of the tumor microenvironment, immune infiltration, and downregulation of tumor-mediated immune suppression, thereby nominating 8803 for treatment consideration in meningiomas.
Year:
2026
Glioblastoma (GBM) is the most prevalent malignant brain tumor with poor prognosis. Although chromatin intratumoral heterogeneity is a characteristic feature of GBM, most current studies are conducted at a single tumor site. To investigate the GBM-specific 3D genome organization and its heterogeneity, we conducted Hi-C experiments in 21 GBM samples from nine patients, along with three normal brain samples. We identified genome subcompartmentalization and chromatin interactions specific to GBM, as well as extensive intertumoral and intratumoral heterogeneity at these levels. We identified copy number variants (CNVs) and structural variations (SVs) and demonstrated how they disrupted 3D genome structures. SVs could not only induce enhancer hijacking but also cause the loss of enhancers to the same gene, both of which contributed to gene dysregulation. Our findings provide insights into the GBM-specific 3D genome organization and the intratumoral heterogeneity of this organization and open avenues for understanding this devastating disease.
Year:
2025
Year:
2025
Year:
2025
Purpose: We recently reported on clinical trials for patients with recurrent glioblastoma where low-intensity pulsed ultrasound and microbubbles (LIPU/MB) improved paclitaxel or carboplatin delivery into the brain. Here, we report variable local tumor control with paclitaxel at the maximal/target dose in our phase I trial (NCT04528680). To address this, we investigated the combination of paclitaxel with carboplatin in preclinical glioma models. Experimental Design: We performed MRI-based analysis to evaluate disease control in patients from our trial. We studied the cytotoxicity of paclitaxel and carboplatin against 11 human glioma lines as monotherapy and in combination at concentrations derived from human intraoperative studies. Synergy was assessed with the Loewe model and the survival benefit evaluated in two xenografts. We examined the effects on cell cycle progression, DNA damage, and apoptosis. Results: Patients treated with paclitaxel and LIPU/MB exhibited variable local tumor control, which correlated with overall survival. We observed limited cross-resistance to paclitaxel and carboplatin in glioma lines, with almost a third of them being exclusively susceptible to one drug. This combination led to susceptibility of 81% of lines and synergy in 55% of them. The combination proved more efficacious in two intracranial xenografts when administered with LIPU/MB, leading to complementary effects on cell cycle arrest. Conclusions: Combining paclitaxel and carboplatin in gliomas may be more efficacious than monotherapy, as in other cancers, due to synergy and independent susceptibility to each drug. These results form the basis for an ongoing phase II trial (NCT04528680) where we investigate this combination with LIPU/MB.
Year:
2024
Meningioma classification and treatment have evolved over the past eight decades. Since Bailey, Cushing, and Eisenhart’s description of meningiomas in the 1920s and 1930s, there have been continual advances in clinical stratification by histopathology, radiography and, most recently, molecular profiling, to improve prognostication and predict response to therapy. Precise and accurate classification is essential to optimizing management for patients with meningioma, which involves surveillance imaging, surgery, primary or adjuvant radiotherapy, and consideration for clinical trials. Currently, the World Health Organization (WHO) grade, extent of resection (EOR), and patient characteristics are used to guide management. While these have demonstrated reliability, a substantial number of seemingly benign lesions recur, suggesting opportunities for improvement of risk stratification. Furthermore, the role of adjuvant radiotherapy for grade 1 and 2 meningioma remains controversial. Over the last decade, numerous studies investigating the molecular drivers of clinical aggressiveness have been reported, with the identification of molecular markers that carry clinical implications as well as biomarkers of radiotherapy response. Here, we review the historical context of current practices, highlight recent molecular discoveries, and discuss the challenges of translating these findings into clinical practice.
Year:
2024
Liposarcoma (LPS) is the most common soft-tissue sarcoma in adults with two major subtypes, well differentiated and dedifferentiated. Both subtypes are characterized with the pathognomonic giant ring or marker chromosomes that harbor high copy-numbers of known oncogenes. Here, we reported a comprehensive molecular characterization of both tumor and normal tissues from the same LPS patients, including whole genome sequencing (WGS), transcriptome, enhancer landscape, and genome-wide 3D genome structure by Hi-C. Tumor-specific transcripts and regulatory elements were identified, and enhancer co-amplification and hijacking events were discovered as novel mechanisms upregulating oncogenes such as MDM2, CDK4 and HMGA2. Combining Hi-C, optical mapping, nanopore long reads and WGS data partially resolved complex structural variations and reconstructed the local genome and the giant chromosome. Overall, this study provides a comprehensive resource for LPS research and offers insights into how altered enhancers and the 3D genome contribute to gene dysregulation in cancer.
Year:
2024
Supplementary Figure 3. Paclitaxel and carboplatin exhibit synergy in vitro. (A) Dose-response matrices illustrating the Loewe synergy score calculated for 11 glioma cell lines at clinically relevant PTX and CBDCA concentrations. (B) Bar charts showing the viability of cell lines treated with PTX, CBDCA, or a combination of both drugs at concentration that showed the highest synergy.
Year:
2024
Supplementary Figure 3. Paclitaxel and carboplatin exhibit synergy in vitro. (A) Dose-response matrices illustrating the Loewe synergy score calculated for 11 glioma cell lines at clinically relevant PTX and CBDCA concentrations. (B) Bar charts showing the viability of cell lines treated with PTX, CBDCA, or a combination of both drugs at concentration that showed the highest synergy.
Year:
2024
Supplementary Figure 1. Paclitaxel delivered with low-intensity pulsed ultrasound and microbubbles leads to variable local tumor control. Coronal T1 with contrast MRI images of patients from our phase I clinical trial (NCT04528680) who received the highest dose of Abraxane (260 mg/m2). We illustrate in green the area covered by the sonication, and observe a variable local tumor control within this region. The five patients presented in the upper (blue) panel exhibited tumor control, while the remaining patients (in red) had tumor growth while on therapy.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (14)
Crismita Dmello
Assistant Professor
Northwestern University Feinberg School of Medicine
Hui Zhang
Professor
Northwestern University Feinberg School of Medicine
SAMEER AGNIHOTRI
Associate Professor with Tenure
University of Pittsburgh School of Medicine
Stephen T. Magill
Assistant Professor
Northwestern University
Zeynep Erson-Omay
Assistant Professor (secondary appointment)
Yale University School of Medicine
Feng Yue
Associate Professor
Northwestern University Feinberg School of Medicine
Tingting Liu
Professor
Southeast University
Adam M Sonabend
Associate Professor, Director of Translational Neuro-oncology
Northwestern University
Tanyeri Barak
Assistant Professor
Yale University
Yu Luan
Assistant Professor
University of Texas Health Science Center at San Antonio
Xinyan Lu
-
Juan Wang
Northwestern University
Ketu Mishra-Gorur
Associate Professor
Yale University
Thomas Sears
Research Associate
Mayo Clinic Florida
Make your next move.
Prepare your application
Review drafts before you send them.